Search Results : Diabetes

1155 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Novel Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
HRAS and KCNQ1
Name 1
HRas proto-oncogene, GTPase
Name2
potassium voltage-gated channel subfamily Q member 1
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • Voltage gated Potassium channels
  • Phase 3 - rapid repolarisation
  • Phase 2 - plateau phase
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
  • Enflurane
  • Promethazine
  • Miconazole
  • Bepridil
  • Dronedarone
  • Azimilide
  • ICA-105665
  • Isavuconazole
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
  • Short QT syndrome
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
  • Atrial fibrillation
  • Type II diabetes mellitus
Novel
Novel
Symbols
S100P and WFS1
Name 1
S100 calcium binding protein P
Name2
wolframin ER transmembrane glycoprotein
Pathway 1
  • Neutrophil degranulation
Pathway 2
  • XBP1(S) activates chaperone genes
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
Drugs 1
  • Cromoglicic acid
Drugs 2
Diseases 1
Diseases 2
  • Wolfram syndrome (WFS); DIDMOAD syndrome
  • Type II diabetes mellitus
Novel
Novel
Symbols
PALS2 and PTF1A
Name 1
protein associated with LIN7 2, MAGUK p55 family member
Name2
pancreas associated transcription factor 1a
Pathway 1
Pathway 2
  • Regulation of gene expression in early pancreatic precursor cells
  • Developmental Lineage of Pancreatic Acinar Cells
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • Permanent neonatal diabetes mellitus (PNDM)
Novel
Novel
Symbols
CALML3 and IL2RA
Name 1
calmodulin like 3
Name2
interleukin 2 receptor subunit alpha
Pathway 1
Pathway 2
  • RAF/MAP kinase cascade
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
Drugs 1
Drugs 2
  • Denileukin diftitox
  • Aldesleukin
  • Basiliximab
  • Daclizumab
  • Inolimomab
  • Camidanlumab tesirine
Diseases 1
Diseases 2
  • Type I diabetes mellitus
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel
Novel
Symbols
FGF2 and IL2
Name 1
fibroblast growth factor 2
Name2
interleukin 2
Pathway 1
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Formation of intermediate mesoderm
  • Formation of the nephric duct
  • TGFBR3 regulates FGF2 signaling
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
Pathway 2
  • RAF/MAP kinase cascade
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
Drugs 1
  • Sucralfate
  • Pentosan polysulfate
  • Heparin
  • 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
  • ABT-510
Drugs 2
  • Pseudoephedrine
  • Cefazolin
  • SP4160
  • N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide
  • 3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One
  • Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate
  • (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid
  • SP2456
  • 2-[2-(2-Cyclohexyl-2-guanidino-acetylamino)-acetylamino]-N-(3-mercapto-propyl)-propionamide
  • Keyhole limpet hemocyanin
  • Girentuximab
  • TG4010
Diseases 1
Diseases 2
  • Graft-versus-host disease
  • Type I diabetes mellitus
Novel
Novel
Symbols
ARF3 and CDK2
Name 1
ARF GTPase 3
Name2
cyclin dependent kinase 2
Pathway 1
  • Synthesis of PIPs at the Golgi membrane
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
Pathway 2
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Factors involved in megakaryocyte development and platelet production
Drugs 1
Drugs 2
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
  • Trilaciclib
Diseases 1
Diseases 2
Novel
Novel
Symbols
CDKN1A and CDK12
Name 1
cyclin dependent kinase inhibitor 1A
Name2
cyclin dependent kinase 12
Pathway 1
  • SCF(Skp2)-mediated degradation of p27/p21
  • AKT phosphorylates targets in the cytosol
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • Transcriptional regulation by RUNX2
  • RUNX3 regulates CDKN1A transcription
  • Neddylation
  • Transcriptional regulation of granulopoiesis
  • FOXO-mediated transcription of cell cycle genes
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by ALK fusions and activated point mutants
  • KEAP1-NFE2L2 pathway
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
Pathway 2
  • TP53 Regulates Transcription of DNA Repair Genes
Drugs 1
  • Valproic acid
  • Arsenic trioxide
Drugs 2
Diseases 1
  • Cervical cancer
Diseases 2
Novel
Novel
Symbols
ATF2 and CYP27B1
Name 1
activating transcription factor 2
Name2
cytochrome P450 family 27 subfamily B member 1
Pathway 1
  • Transcriptional activation of mitochondrial biogenesis
  • HATs acetylate histones
  • Activation of the AP-1 family of transcription factors
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Estrogen-dependent gene expression
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Heme signaling
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
Pathway 2
  • Vitamin D (calciferol) metabolism
  • Vitamins
  • Defective CYP27B1 causes VDDR1A
Drugs 1
  • Pseudoephedrine
Drugs 2
  • Alfacalcidol
Diseases 1
Diseases 2
  • Type I diabetes mellitus
Novel
Novel
Symbols
CAMLG and STT3B
Name 1
calcium modulating ligand
Name2
STT3 oligosaccharyltransferase complex catalytic subunit B
Pathway 1
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
Pathway 2
  • Asparagine N-linked glycosylation
  • Maturation of spike protein
  • Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
  • PD-L1(CD274) glycosylation and translocation to plasma membrane
Drugs 1
  • Cyclosporine
  • Voclosporin
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
IGF1R and PCSK6
Name 1
insulin like growth factor 1 receptor
Name2
proprotein convertase subtilisin/kexin type 6
Pathway 1
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • IRS-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Extra-nuclear estrogen signaling
  • Respiratory syncytial virus (RSV) attachment and entry
Pathway 2
  • Signaling by NODAL
  • NGF processing
  • Formation of the cornified envelope
  • Assembly of active LPL and LIPC lipase complexes
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
Drugs 1
  • Insulin human
  • Insulin lispro
  • Insulin glargine
  • Insulin pork
  • Mecasermin
  • Insulin aspart
  • Insulin detemir
  • Insulin glulisine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • ATL1101
  • XL228
  • rhIGFBP-3
  • Linsitinib
  • Teprotumumab
  • (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione
  • 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE
  • Nandrolone decanoate
  • Somatrem
  • Insulin beef
  • Insulin degludec
  • Insulin argine
  • Insulin peglispro
  • Insulin tregopil
  • Dalotuzumab
  • Cixutumumab
  • Brigatinib
  • Mecasermin rinfabate
  • BMS-754807
  • KW-2450 free base
Drugs 2
Diseases 1
  • Synovial sarcoma
  • Malignant pleural mesothelioma
Diseases 2
Novel
Novel
Symbols
LOX and ZNF608
Name 1
lysyl oxidase
Name2
zinc finger protein 608
Pathway 1
  • Elastic fibre formation
  • Crosslinking of collagen fibrils
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
RHOA and KLRG1
Name 1
ras homolog family member A
Name2
killer cell lectin like receptor G1
Pathway 1
  • GPVI-mediated activation cascade
  • Axonal growth inhibition (RHOA activation)
  • PI3K/AKT activation
  • Axonal growth stimulation
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • G beta:gamma signalling through PI3Kgamma
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • PCP/CE pathway
  • G alpha (12/13) signalling events
  • Sema4D mediated inhibition of cell attachment and migration
  • Sema4D induced cell migration and growth-cone collapse
  • Sema4D induced cell migration and growth-cone collapse
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases activate CIT
  • RHO GTPases activate KTN1
  • RHO GTPases Activate ROCKs
  • RHO GTPases Activate ROCKs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Rhotekin and Rhophilins
  • RHO GTPases Activate Rhotekin and Rhophilins
  • Ovarian tumor domain proteases
  • ERBB2 Regulates Cell Motility
  • Neutrophil degranulation
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RHOA GTPase cycle
  • SLIT2:ROBO1 increases RHOA activity
  • RHOC GTPase cycle
Pathway 2
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Drugs 1
  • Guanosine-5'-Diphosphate
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
FER and PCSK1
Name 1
FER tyrosine kinase
Name2
proprotein convertase subtilisin/kexin type 1
Pathway 1
  • Signaling by SCF-KIT
Pathway 2
  • Peptide hormone biosynthesis
  • Insulin processing
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Synthesis, secretion, and deacylation of Ghrelin
Drugs 1
  • Fostamatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
F8 and SORCS3
Name 1
coagulation factor VIII
Name2
sortilin related VPS10 domain containing receptor 3
Pathway 1
  • Platelet degranulation
  • Intrinsic Pathway of Fibrin Clot Formation
  • Common Pathway of Fibrin Clot Formation
  • Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • Defective factor IX causes thrombophilia
  • Defective F8 accelerates dissociation of the A2 domain
  • Defective F8 cleavage by thrombin
  • Defective F8 binding to von Willebrand factor
  • Defective F8 binding to the cell membrane
  • Defective cofactor function of FVIIIa variant
  • Defective F8 secretion
  • Defective F9 variant does not activate FX
  • Defective F8 sulfation at Y1699
Pathway 2
Drugs 1
  • Drotrecogin alfa
  • Coagulation Factor IX (Recombinant)
  • TB-402
  • Thrombin
  • Protein C
  • Human thrombin
  • Thrombin alfa
  • Vonicog alfa
  • Von Willebrand factor human
  • Anti-inhibitor coagulant complex
  • Coagulation Factor IX Human
  • Nonacog beta pegol
  • Damoctocog alfa pegol
  • Rurioctocog alfa pegol
Drugs 2
Diseases 1
  • Hemophilia; Hemophilia A (HEMA); Hemophilia B (HEMB); von Willebrand disease (VWD)
Diseases 2
Novel
Novel
Symbols
AP2M1 and LPP
Name 1
adaptor related protein complex 2 subunit mu 1
Name2
LIM domain containing preferred translocation partner in lipoma
Pathway 1
  • Nef mediated downregulation of CD28 cell surface expression
  • Nef Mediated CD4 Down-regulation
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Nef Mediated CD8 Down-regulation
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Potential therapeutics for SARS
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
BMPR2 and IGFBP2
Name 1
bone morphogenetic protein receptor type 2
Name2
insulin like growth factor binding protein 2
Pathway 1
  • Signaling by BMP
Pathway 2
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Drugs 1
  • Dibotermin alfa
  • Fostamatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
FXR1 and USP46
Name 1
FMR1 autosomal homolog 1
Name2
ubiquitin specific peptidase 46
Pathway 1
  • Signaling by BRAF and RAF1 fusions
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
SETDB1 and TSPAN15
Name 1
SET domain bifurcated histone lysine methyltransferase 1
Name2
tetraspanin 15
Pathway 1
  • PKMTs methylate histone lysines
  • Regulation of endogenous retroelements by KRAB-ZFP proteins
  • Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
  • Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
Pathway 2
  • Amyloid fiber formation
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
EIF4A1 and MYH10
Name 1
eukaryotic translation initiation factor 4A1
Name2
myosin heavy chain 10
Pathway 1
  • ISG15 antiviral mechanism
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Deadenylation of mRNA
  • Deadenylation of mRNA
  • Translation initiation complex formation
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
  • Ribosomal scanning and start codon recognition
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • M-decay: degradation of maternal mRNAs by maternally stored factors
  • Z-decay: degradation of maternal mRNAs by zygotically expressed factors
Pathway 2
  • EPHA-mediated growth cone collapse
  • Sema4D induced cell migration and growth-cone collapse
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases Activate ROCKs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
Drugs 1
  • Copper
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
NCOA1 and ZNF512
Name 1
nuclear receptor coactivator 1
Name2
zinc finger protein 512
Pathway 1
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • Recycling of bile acids and salts
  • Synthesis of bile acids and bile salts
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Endogenous sterols
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • HATs acetylate histones
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
  • Cytoprotection by HMOX1
  • Heme signaling
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
Pathway 2
Drugs 1
  • Genistein
  • Corticosterone
  • Prinaberel
  • ERB-196
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
  • TO-901317
  • 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
  • 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
  • 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
  • GW-590735
  • 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
  • 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
  • (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol
  • 3,20-Pregnanedione
  • Indeglitazar
  • (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid
  • Myristic acid
  • 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
  • Aleglitazar
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
HRAS and KCNQ1
Name 1
HRas proto-oncogene, GTPase
Name2
potassium voltage-gated channel subfamily Q member 1
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • Voltage gated Potassium channels
  • Phase 3 - rapid repolarisation
  • Phase 2 - plateau phase
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
  • Enflurane
  • Promethazine
  • Miconazole
  • Bepridil
  • Dronedarone
  • Azimilide
  • ICA-105665
  • Isavuconazole
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
  • Short QT syndrome
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
  • Atrial fibrillation
  • Type II diabetes mellitus
Novel
Symbols
S100P and WFS1
Name 1
S100 calcium binding protein P
Name2
wolframin ER transmembrane glycoprotein
Pathway 1
  • Neutrophil degranulation
Pathway 2
  • XBP1(S) activates chaperone genes
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
Drugs 1
  • Cromoglicic acid
Drugs 2
Diseases 1
Diseases 2
  • Wolfram syndrome (WFS); DIDMOAD syndrome
  • Type II diabetes mellitus
Novel
Symbols
PALS2 and PTF1A
Name 1
protein associated with LIN7 2, MAGUK p55 family member
Name2
pancreas associated transcription factor 1a
Pathway 1
Pathway 2
  • Regulation of gene expression in early pancreatic precursor cells
  • Developmental Lineage of Pancreatic Acinar Cells
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • Permanent neonatal diabetes mellitus (PNDM)
Novel
Symbols
CALML3 and IL2RA
Name 1
calmodulin like 3
Name2
interleukin 2 receptor subunit alpha
Pathway 1
Pathway 2
  • RAF/MAP kinase cascade
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
Drugs 1
Drugs 2
  • Denileukin diftitox
  • Aldesleukin
  • Basiliximab
  • Daclizumab
  • Inolimomab
  • Camidanlumab tesirine
Diseases 1
Diseases 2
  • Type I diabetes mellitus
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel
Symbols
FGF2 and IL2
Name 1
fibroblast growth factor 2
Name2
interleukin 2
Pathway 1
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Formation of intermediate mesoderm
  • Formation of the nephric duct
  • TGFBR3 regulates FGF2 signaling
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
Pathway 2
  • RAF/MAP kinase cascade
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
Drugs 1
  • Sucralfate
  • Pentosan polysulfate
  • Heparin
  • 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
  • ABT-510
Drugs 2
  • Pseudoephedrine
  • Cefazolin
  • SP4160
  • N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide
  • 3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One
  • Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate
  • (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid
  • SP2456
  • 2-[2-(2-Cyclohexyl-2-guanidino-acetylamino)-acetylamino]-N-(3-mercapto-propyl)-propionamide
  • Keyhole limpet hemocyanin
  • Girentuximab
  • TG4010
Diseases 1
Diseases 2
  • Graft-versus-host disease
  • Type I diabetes mellitus
Novel
Symbols
ARF3 and CDK2
Name 1
ARF GTPase 3
Name2
cyclin dependent kinase 2
Pathway 1
  • Synthesis of PIPs at the Golgi membrane
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
Pathway 2
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Factors involved in megakaryocyte development and platelet production
Drugs 1
Drugs 2
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
  • Trilaciclib
Diseases 1
Diseases 2
Novel
Symbols
CDKN1A and CDK12
Name 1
cyclin dependent kinase inhibitor 1A
Name2
cyclin dependent kinase 12
Pathway 1
  • SCF(Skp2)-mediated degradation of p27/p21
  • AKT phosphorylates targets in the cytosol
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • Transcriptional regulation by RUNX2
  • RUNX3 regulates CDKN1A transcription
  • Neddylation
  • Transcriptional regulation of granulopoiesis
  • FOXO-mediated transcription of cell cycle genes
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by ALK fusions and activated point mutants
  • KEAP1-NFE2L2 pathway
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
Pathway 2
  • TP53 Regulates Transcription of DNA Repair Genes
Drugs 1
  • Valproic acid
  • Arsenic trioxide
Drugs 2
Diseases 1
  • Cervical cancer
Diseases 2
Novel
Symbols
ATF2 and CYP27B1
Name 1
activating transcription factor 2
Name2
cytochrome P450 family 27 subfamily B member 1
Pathway 1
  • Transcriptional activation of mitochondrial biogenesis
  • HATs acetylate histones
  • Activation of the AP-1 family of transcription factors
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Estrogen-dependent gene expression
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Heme signaling
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
Pathway 2
  • Vitamin D (calciferol) metabolism
  • Vitamins
  • Defective CYP27B1 causes VDDR1A
Drugs 1
  • Pseudoephedrine
Drugs 2
  • Alfacalcidol
Diseases 1
Diseases 2
  • Type I diabetes mellitus
Novel
Symbols
CAMLG and STT3B
Name 1
calcium modulating ligand
Name2
STT3 oligosaccharyltransferase complex catalytic subunit B
Pathway 1
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
Pathway 2
  • Asparagine N-linked glycosylation
  • Maturation of spike protein
  • Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
  • PD-L1(CD274) glycosylation and translocation to plasma membrane
Drugs 1
  • Cyclosporine
  • Voclosporin
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
IGF1R and PCSK6
Name 1
insulin like growth factor 1 receptor
Name2
proprotein convertase subtilisin/kexin type 6
Pathway 1
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • IRS-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Extra-nuclear estrogen signaling
  • Respiratory syncytial virus (RSV) attachment and entry
Pathway 2
  • Signaling by NODAL
  • NGF processing
  • Formation of the cornified envelope
  • Assembly of active LPL and LIPC lipase complexes
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
Drugs 1
  • Insulin human
  • Insulin lispro
  • Insulin glargine
  • Insulin pork
  • Mecasermin
  • Insulin aspart
  • Insulin detemir
  • Insulin glulisine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • ATL1101
  • XL228
  • rhIGFBP-3
  • Linsitinib
  • Teprotumumab
  • (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione
  • 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE
  • Nandrolone decanoate
  • Somatrem
  • Insulin beef
  • Insulin degludec
  • Insulin argine
  • Insulin peglispro
  • Insulin tregopil
  • Dalotuzumab
  • Cixutumumab
  • Brigatinib
  • Mecasermin rinfabate
  • BMS-754807
  • KW-2450 free base
Drugs 2
Diseases 1
  • Synovial sarcoma
  • Malignant pleural mesothelioma
Diseases 2
Novel
Symbols
LOX and ZNF608
Name 1
lysyl oxidase
Name2
zinc finger protein 608
Pathway 1
  • Elastic fibre formation
  • Crosslinking of collagen fibrils
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
RHOA and KLRG1
Name 1
ras homolog family member A
Name2
killer cell lectin like receptor G1
Pathway 1
  • GPVI-mediated activation cascade
  • Axonal growth inhibition (RHOA activation)
  • PI3K/AKT activation
  • Axonal growth stimulation
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • G beta:gamma signalling through PI3Kgamma
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • PCP/CE pathway
  • G alpha (12/13) signalling events
  • Sema4D mediated inhibition of cell attachment and migration
  • Sema4D induced cell migration and growth-cone collapse
  • Sema4D induced cell migration and growth-cone collapse
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases activate CIT
  • RHO GTPases activate KTN1
  • RHO GTPases Activate ROCKs
  • RHO GTPases Activate ROCKs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Rhotekin and Rhophilins
  • RHO GTPases Activate Rhotekin and Rhophilins
  • Ovarian tumor domain proteases
  • ERBB2 Regulates Cell Motility
  • Neutrophil degranulation
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RHOA GTPase cycle
  • SLIT2:ROBO1 increases RHOA activity
  • RHOC GTPase cycle
Pathway 2
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Drugs 1
  • Guanosine-5'-Diphosphate
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
FER and PCSK1
Name 1
FER tyrosine kinase
Name2
proprotein convertase subtilisin/kexin type 1
Pathway 1
  • Signaling by SCF-KIT
Pathway 2
  • Peptide hormone biosynthesis
  • Insulin processing
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Synthesis, secretion, and deacylation of Ghrelin
Drugs 1
  • Fostamatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
F8 and SORCS3
Name 1
coagulation factor VIII
Name2
sortilin related VPS10 domain containing receptor 3
Pathway 1
  • Platelet degranulation
  • Intrinsic Pathway of Fibrin Clot Formation
  • Common Pathway of Fibrin Clot Formation
  • Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • Defective factor IX causes thrombophilia
  • Defective F8 accelerates dissociation of the A2 domain
  • Defective F8 cleavage by thrombin
  • Defective F8 binding to von Willebrand factor
  • Defective F8 binding to the cell membrane
  • Defective cofactor function of FVIIIa variant
  • Defective F8 secretion
  • Defective F9 variant does not activate FX
  • Defective F8 sulfation at Y1699
Pathway 2
Drugs 1
  • Drotrecogin alfa
  • Coagulation Factor IX (Recombinant)
  • TB-402
  • Thrombin
  • Protein C
  • Human thrombin
  • Thrombin alfa
  • Vonicog alfa
  • Von Willebrand factor human
  • Anti-inhibitor coagulant complex
  • Coagulation Factor IX Human
  • Nonacog beta pegol
  • Damoctocog alfa pegol
  • Rurioctocog alfa pegol
Drugs 2
Diseases 1
  • Hemophilia; Hemophilia A (HEMA); Hemophilia B (HEMB); von Willebrand disease (VWD)
Diseases 2
Novel
Symbols
AP2M1 and LPP
Name 1
adaptor related protein complex 2 subunit mu 1
Name2
LIM domain containing preferred translocation partner in lipoma
Pathway 1
  • Nef mediated downregulation of CD28 cell surface expression
  • Nef Mediated CD4 Down-regulation
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Nef Mediated CD8 Down-regulation
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Potential therapeutics for SARS
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
BMPR2 and IGFBP2
Name 1
bone morphogenetic protein receptor type 2
Name2
insulin like growth factor binding protein 2
Pathway 1
  • Signaling by BMP
Pathway 2
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Drugs 1
  • Dibotermin alfa
  • Fostamatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
FXR1 and USP46
Name 1
FMR1 autosomal homolog 1
Name2
ubiquitin specific peptidase 46
Pathway 1
  • Signaling by BRAF and RAF1 fusions
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
SETDB1 and TSPAN15
Name 1
SET domain bifurcated histone lysine methyltransferase 1
Name2
tetraspanin 15
Pathway 1
  • PKMTs methylate histone lysines
  • Regulation of endogenous retroelements by KRAB-ZFP proteins
  • Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
  • Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
Pathway 2
  • Amyloid fiber formation
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
EIF4A1 and MYH10
Name 1
eukaryotic translation initiation factor 4A1
Name2
myosin heavy chain 10
Pathway 1
  • ISG15 antiviral mechanism
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Deadenylation of mRNA
  • Deadenylation of mRNA
  • Translation initiation complex formation
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
  • Ribosomal scanning and start codon recognition
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • M-decay: degradation of maternal mRNAs by maternally stored factors
  • Z-decay: degradation of maternal mRNAs by zygotically expressed factors
Pathway 2
  • EPHA-mediated growth cone collapse
  • Sema4D induced cell migration and growth-cone collapse
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases Activate ROCKs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
Drugs 1
  • Copper
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
NCOA1 and ZNF512
Name 1
nuclear receptor coactivator 1
Name2
zinc finger protein 512
Pathway 1
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • Recycling of bile acids and salts
  • Synthesis of bile acids and bile salts
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Endogenous sterols
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • HATs acetylate histones
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
  • Cytoprotection by HMOX1
  • Heme signaling
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
Pathway 2
Drugs 1
  • Genistein
  • Corticosterone
  • Prinaberel
  • ERB-196
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
  • TO-901317
  • 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
  • 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
  • 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
  • GW-590735
  • 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
  • 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
  • (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol
  • 3,20-Pregnanedione
  • Indeglitazar
  • (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid
  • Myristic acid
  • 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
  • Aleglitazar
Drugs 2
Diseases 1
Diseases 2

Page 1 out of 58 pages

© Madhavi K. Ganapathiraju 2012-2025